Skip to content
Screener

Abbott ABT Established Pharmaceuticals — Goodwill, non-deductible

Other segment segments

Medical Devices
$17.3B0.0%
Diagnostic Products
$15B+317%
Nutritional Products
$300M+5.3%

Similar metrics at other companies

Baxter International logo
BAXPharmaceuticals — Goodwill
$569M+2.2%
Bausch + Lomb logo
BLCOPharmaceuticals — Goodwill
$720M-3.7%
Opko Health logo
OPKPharmaceutical — Goodwill
$318.07M-0.8%
McKesson logo
MCKNorth American Pharmaceutical — Goodwill
$2.76B
Johnson & Johnson logo
JNJPharmaceutical — Goodwill (Note 3)
$14.76B+3.0%
AMP
AMPHFinished Pharmaceutical Products — Goodwill
$3.31M-2.5%

Other financials

Income statement

See full
Revenue$12.6B+13.0%
Gross profit$7.3B+15.6%
Operating income$1.7B-17.5%
Net income$928.0M-47.8%
EPS (diluted)$0.53-47.5%

Balance sheet

See full
Cash & equivalents$5.1B-26.6%
Total debt$32.6B+143%
Total equity$51.1B+1.1%
Total assets$109.22B+30.0%

Cash flow

See full
Operating cash flow$2.5B+21.5%
CapEx$497.0M-1.0%
Free cash flow$2.0B+28.9%

Valuation

See full
Market cap$182.92B-19.7%
Enterprise value$210.42B-10.2%
P/E33.7×+17.4×
P/S3.9×-1.4×

Profitability

See full
Gross margin56.6%+0.6pp
Operating margin15.8%-1.7pp
Net margin11.6%-20.8pp
FCF margin16.8%+1.1pp

Returns & leverage

See full
Return on equity10.7%-20.4pp
Debt / equity0.6×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The source filing: Abbott’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050134

The total amount of goodwill reported was $35.2 billion at June 30, 2026, and $24.0 billion at December 31, 2025. Goodwill increased by $11.4 billion in the first six months of 2026 due to the completion of the Exact Sciences acquisition. Foreign currency translation adjustments decreased goodwill by $0.2 billion in the first six months of 2026. The amount of goodwill related to reportable segments at June 30, 2026, was $2.7 billion for the Established Pharmaceutical Products segment, $0.3 billion for the Nutritional Products segment, $15.0 billion for the Diagnostic Products segment, and $17.3 billion for the Medical Devices segment. The Diagnostic Products segment includes the amount of goodwill related to the Exact Sciences acquisition. There were no reductions of goodwill relating to impairments in the first six months of 2026.

Item 1. Financial Statements and Supplementary Data

FAQ

What is Abbott's established pharmaceuticals — goodwill, non-deductible?
Abbott (ABT) reported established pharmaceuticals — goodwill, non-deductible of $2.7B in Q2 2026.
How has Abbott's established pharmaceuticals — goodwill, non-deductible changed year-over-year?
Abbott's established pharmaceuticals — goodwill, non-deductible decreased by 0.0% year-over-year, from $2.7B to $2.7B.
What is the long-term trend for Abbott's established pharmaceuticals — goodwill, non-deductible?
Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — goodwill, non-deductible has grown at a -1.8% compound annual growth rate (CAGR), from $11.5B to $10.7B.
What does established pharmaceuticals — goodwill, non-deductible mean?
This metric represents the portion of goodwill associated with the Established Pharmaceuticals segment that is not tax-deductible. It reflects the premium paid over the fair value of net identifiable assets during acquisitions within this specific business unit, which cannot be amortized for tax purposes. This figure is a critical indicator of the long-term carrying value of intangible assets and potential impairment risks within the company's branded generic drug portfolio.

Ask your AI about Abbott's established pharmaceuticals — goodwill, non-deductible.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude